William J. Eckerman

William J. Eckerman

Auto-generated profile, based on publicly available information

William J. Eckerman

Michigan State University 1 East Lansing, MI

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
LVLexi Vu
Lexi Vu
NGNicholas S. Giacobbi
Nicholas S. Giacobbi
MKMohamed I. Khalil
Mohamed I. Khalil
CYCanchai Yang
Canchai Yang
WEWilliam J. Eckerman
William J. Eckerman
DPDohun Pyeon
Dohun Pyeon
Antigen presentation by MHC class I (MHC-I) is critical for tumor cell killing by CD8+ T cells. In human papillomavirus–positive head and neck cancer (HPV+ HNC), in which MHC-I downregulation is frequent despite favorable immune cell infiltration, lower MHC-I levels are associated with poor responses to immune checkpoint inhibitor therapy. However, the mechanism of MHC-I degradation remains elusive. Genome-wide CRISPR screens in HPV+ HNC identified components of the ULK1 and PIK3C3 autophagy initiation complexes among top negative regulators of cell surface MHC-I. In contrast, inhibiting postinitiation stages of autophagy did not restore cell surface MHC-I, highlighting a critical role for autophagy initiation in regulation of MHC-I. Mechanistically, we showed that MHC-I is recruited from the endoplasmic reticulum to autophagosomes by the cargo receptor NDP52. Finally, inhibition of autophagy initiation suppressed HPV+ HNC tumor growth in vivo and enhanced the CD8+ T cell–mediated antitumor response. Our findings suggest that autophagic degradation of MARCHF8-ubiquitinated MHC-I is a key immune evasion mechanism in HPV+ HNC.